Published in

Oxford University Press, International Journal of Pharmacy Practice, 2021

DOI: 10.1093/ijpp/riab032

Links

Tools

Export citation

Search in Google Scholar

Agreement between pharmaceutical claims data and patient-reported medication use after stroke

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Abstract Objectives To assess the agreement between pharmaceutical claims data and patient-reported medication use after stroke. Methods Claims data from the Pharmaceutical Benefits Scheme were used to estimate medication use for a subset of participants registered in the Australian Stroke Clinical Registry in 2016. Estimates on medication use were validated against patient-reported responses (considered the reference standard). Key findings For antihypertensive and lipid-lowering medications, the sensitivity of claims data was excellent (85–87%) and the specificity was good (73–78%). Whereas for antithrombotic medications, sensitivity was modest (61%), but specificity was excellent (85%). Conclusions Pharmaceutical claims data can be used to infer medication use after stroke with mostly good to excellent sensitivity and specificity compared with the patient report.